Alnylam制药公司的库存在Q1 2022年增长了11%,尽管出口信贷基金减少了其持有量。 Alnylam Pharmaceuticals' stock rose 11% in Q1 2022, despite an ETF reducing its holdings.

生物制药公司Alnylam Pharmaceuticals在2022年第一季度的股价上了11%,尽管Mirae Asset Global ETFs Holdings公司的股票减少了5.3%. Alnylam Pharmaceuticals, a biopharmaceutical company, saw its stock rise by 11% in the first quarter of 2022, despite Mirae Asset Global ETFs Holdings reducing its holdings by 5.3%. 该公司的市场上限为61.07亿美元,它报告了强劲的Q2,收入为0.32 EPS,超过分析师的估计。 The company's market cap is $61.07 billion, and it reported a strong Q2 with earnings of $0.32 EPS, surpassing analyst estimates. Alnylam公司以RNA干扰治疗为主,对氨基甲状腺素中毒和超恶性甲状腺素等疾病进行治疗。 Alnylam focuses on RNA interference-based therapeutics and has treatments for conditions like amyloidosis and hyperoxaluria. 机构投资者拥有公司大约92.97%的股份。 Institutional investors own about 92.97% of the company's stock.